After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Docquity, Southeast Asia's largest network of healthcare professionals (HCPs), and global healthcare company Novartis announce a multi-year partnership in Malaysia to address the rise of retinal ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

omnichannel commercial capabilities under its Awareness to Advocacy (A2A) Program, Novartis enhances retinal health education for thousands of ophthalmologists and medical retina doctors across the ...

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...

Stanway (pictured) said commercial concerns were the most likely reason for Novartis to get cold feet on the project. He told pharmaphorum in an interview: “Some commentators say they may be ...

The unpaid debt on the building was $20.6 million at the time of the property’s acquisition, according to documents filed on ...

When we last looked at Lantheus in May, its stock was trading just under $80 a share. As a reminder, Lantheus Holdings, Inc.

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

EMERYVILLE — A high-profile East Bay office building has been bought in a deal that shows commercial property values in the ...

EMERYVILLE — A high-profile East Bay office building has been bought in a deal that shows commercial property values in the ...